Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1750-1172
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe? ; volume:6 ; number:1 ; day:5 ; month:9 ; year:2011 ; pages:1-11 ; date:12.2011
Orphanet journal of rare diseases ; 6, Heft 1 (5.9.2011), 1-11, 12.2011
- Urheber
-
Brabers, Anne EM
- Beteiligte Personen und Organisationen
-
Moors, Ellen HM
van Weely, Sonja
de Vrueh, Remco LA
SpringerLink (Online service)
- DOI
-
10.1186/1750-1172-6-59
- URN
-
urn:nbn:de:1111-2016050119913
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Brabers, Anne EM
- Moors, Ellen HM
- van Weely, Sonja
- de Vrueh, Remco LA
- SpringerLink (Online service)
Ähnliche Objekte (12)
Comparing access to orphan medicinal products in Europe
The European challenges of funding orphan medicinal products
Clinical evidence for orphan medicinal products-a cause for concern?
Off-label use of orphan medicinal products: a Belgian qualitative study
Costs of orphan medicinal products: longitudinal analysis of expenditure in Wales
Establishment of a value assessment framework for orphan medicinal products in China
No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products - a pilot study
Development and validation of COMPASS: clinical evidence of orphan medicinal products – an assessment tool
Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties
Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders
Natural products in medicinal chemistry
Publication of clinical trials on medicinal products: follow-up on trials authorized in Hungary
Comparing access to orphan medicinal products in Europe
The European challenges of funding orphan medicinal products
Clinical evidence for orphan medicinal products-a cause for concern?
Off-label use of orphan medicinal products: a Belgian qualitative study
Costs of orphan medicinal products: longitudinal analysis of expenditure in Wales
Establishment of a value assessment framework for orphan medicinal products in China
No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products - a pilot study
Development and validation of COMPASS: clinical evidence of orphan medicinal products – an assessment tool
Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties
Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders
Natural products in medicinal chemistry
Publication of clinical trials on medicinal products: follow-up on trials authorized in Hungary
Comparing access to orphan medicinal products in Europe
The European challenges of funding orphan medicinal products
Clinical evidence for orphan medicinal products-a cause for concern?
Off-label use of orphan medicinal products: a Belgian qualitative study
Costs of orphan medicinal products: longitudinal analysis of expenditure in Wales
Establishment of a value assessment framework for orphan medicinal products in China
No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products - a pilot study
Development and validation of COMPASS: clinical evidence of orphan medicinal products – an assessment tool
Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties
Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders
Natural products in medicinal chemistry